National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 59355-59356 [05-20431]
Download as PDF
<![CDATA[
59355
Federal Register / Vol. 70, No. 196 / Wednesday, October 12, 2005 / Notices
TABLE 3.—ESTIMATED ANNUAL REPORTING AND RECORDKEEPING BURDEN FOR BIOLOGICS1—Continued
REPORTING BURDEN
No. of
Respondents
21 CFR Section
312.54(a) and (b)
No. of Responses
per Respondent
1
312.55(b)
Total Annual
Responses
Hours per
Response
1
48
48
1
Total Hours
138
2.5
347
48
16,656
14
1.6
23
80
1,840
8
8
64
21,185
24
508,440
312.56(b) and (d)
312.58(a)
8
312.64(a) through (d)
1
6,003
3.5
312.70(a)
6
1
6
40
240
312.110(b)
21
1
21
75
1,575
312.130(d)
1
1
1
8
8
Total reporting burden
4,338,643
RECORDKEEPING BURDEN
No. of
Recordkeepers
21 CFR Section
Annual Frequency
per Recordkeeping
Total Annual
Records
Hours per
Record
Total Hours
312.52(a)
139
1.4
200
2
400
312.57(a) and (b)
433
2.6
1,114
100
111,400
312.62(a)
5,570
1
5,570
40
222,800
312.62(b)
5,570
10
55,700
40
2,228,000
312.160(a)(3)
146
1.4
211
0.5
105.5
312.160(c)
146
1.4
211
0.5
105.5
Total recordkeeping burden
2,562,811
Total biologics burden hours
6,901,454
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
TABLE 4.—ESTIMATED ANNUAL REPORTING AND RECORDKEEPING BURDEN FOR HUMAN DRUGS AND BIOLOGICS1
Total human drugs burden hours ........................................................................................................................................................
Total biologics burden hours ...............................................................................................................................................................
64,475,247
6,901,454
Total burden hours ..............................................................................................................................................................................
71,376,701
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
Dated: October 3, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–20362 Filed 10–11–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Aug<31>2005
19:48 Oct 11, 2005
Jkt 208001
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel. ‘‘Review of an Unsolicited
P01.’’
Date: October 26, 2005.
Time: 10 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge 6700, 6700B Rockledge Drive,
Bethesda, MD 20817, (Telephone Conference
Call).
Contact Person: Cheryl K. Lapham, PhD,
Scientific Review Administrator, Scientific
Review Program, National Institute of Allergy
and Infectious Diseases, DEA/NIH/DHHS,
6700–B Rockledge Drive, MSC 7616, Room
3127, Bethesda, MD 20892–7616, 301–402–
4598, clapham@niaid.nih.gov.
E:\FR\FM\12OCN1.SGM
12OCN1
59356
Federal Register / Vol. 70, No. 196 / Wednesday, October 12, 2005 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: October 3, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–20431 Filed 10–11–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
NIDDK, National Institues of Health, Room
772, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–2242,
sahaia@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: October 02, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–20432 Filed 10–11–05; 8:45am]
National Institutes of Health
BILLING CODE Code 4140–01–M
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel. Research Training
in Pediatric Gastroenterology.
Date: October 26, 2005.
Time: 11 a.m. to 12 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, One
Democracy Plaza, 6701 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Xiaodu Guo, MD, PhD,
Scientific Review Administrator, Review
Branch, DEA, NIDDK, National Institutes of
Health, Room 705, 6707 Democracy
Boulevard, Bethesda, MD 20892–5452, (301)
594–4719, guox@extra.niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel. Sphincter of Oddi
Dysfunction.
Date: November 1, 2005.
Time: 1:30 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: Atul Sahai, PhD, Scientific
Review Administrator, Review Branch, DEA,
VerDate Aug<31>2005
19:48 Oct 11, 2005
Jkt 208001
National Institutes of Health
National Library of Medicine; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the Board of Scientific
Counselors, National Library of
Medicine, October 25, 2005, 9 a.m. to
October 25, 2005, 5 p.m., National
Library of Medicine, Building 38, Board
Room, 2nd Floor, 8600 Rockville Pike,
Bethesda, MD 20892 which was
published in the Federal Register on
August 16, 2005, 70 FR 48166.
In addition to the October 25, 2005
meeting, there will be a meeting on
October 24, 2005 from 5 p.m. to 7 p.m.
at the Bethesda Marriott, 5151 Pooks
Hill Road, Bethesda, Maryland 20892.
The meeting is partially closed to the
public.
Dated: October 3, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–20430 Filed 10–11–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of Laboratories Which
Meet Minimum Standards To Engage in
Urine Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories currently
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
certified to meet the standards of
Subpart C of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908),
on September 30, 1997 (62 FR 51118),
and on April 13, 2004 (69 FR 19644).
A notice listing all currently certified
laboratories is published in the Federal
Register during the first week of each
month. If any laboratory’s certification
is suspended or revoked, the laboratory
will be omitted from subsequent lists
until such time as it is restored to full
certification under the Mandatory
Guidelines.
If any laboratory has withdrawn from
the HHS National Laboratory
Certification Program (NLCP) during the
past month, it will be listed at the end,
and will be omitted from the monthly
listing thereafter.
This notice is also available on the
Internet at https://workplace.samhsa.gov
and https://www.drugfreeworkplace.gov.
FOR FURTHER INFORMATION CONTACT: Mrs.
Giselle Hersh or Dr. Walter Vogl,
Division of Workplace Programs,
SAMHSA/CSAP, Room 2–1035, 1 Choke
Cherry Road, Rockville, Maryland
20857; (240) 276–2600 (voice), (240)
276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were developed
in accordance with Executive Order
12564 and section 503 of Public Law
100–71. Subpart C of the Mandatory
Guidelines, ‘‘Certification of
Laboratories Engaged in Urine Drug
Testing for Federal Agencies,’’ sets strict
standards that laboratories must meet in
order to conduct drug and specimen
validity tests on urine specimens for
Federal agencies. To become certified,
an applicant laboratory must undergo
three rounds of performance testing plus
an on-site inspection. To maintain that
certification, a laboratory must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories which claim to be in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A laboratory
must have its letter of certification from
HHS/SAMHSA (formerly: HHS/NIDA)
which attests that it has met minimum
standards.
In accordance with Subpart C of the
Mandatory Guidelines dated April 13,
2004 (69 FR 19644), the following
laboratories meet the minimum
E:\FR\FM\12OCN1.SGM
12OCN1
]]>Agencies
[Federal Register Volume 70, Number 196 (Wednesday, October 12, 2005)]
[Notices]
[Pages 59355-59356]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-20431]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel. ``Review of an Unsolicited P01.''
Date: October 26, 2005.
Time: 10 a.m. to 1 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge 6700, 6700B
Rockledge Drive, Bethesda, MD 20817, (Telephone Conference Call).
Contact Person: Cheryl K. Lapham, PhD, Scientific Review
Administrator, Scientific Review Program, National Institute of
Allergy and Infectious Diseases, DEA/NIH/DHHS, 6700-B Rockledge
Drive, MSC 7616, Room 3127, Bethesda, MD 20892-7616, 301-402-4598,
clapham@niaid.nih.gov.
[[Page 59356]]
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: October 3, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-20431 Filed 10-11-05; 8:45 am]
BILLING CODE 4140-01-M
